Compare HBB & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBB | ARMP |
|---|---|---|
| Founded | 1904 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 295.5M |
| IPO Year | 2017 | 1996 |
| Metric | HBB | ARMP |
|---|---|---|
| Price | $19.57 | $8.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 15.5K | ★ 72.3K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $606,852,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $75.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.72 | $1.74 |
| 52 Week High | $21.84 | $14.98 |
| Indicator | HBB | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 52.60 | 41.76 |
| Support Level | $17.95 | $5.14 |
| Resistance Level | $20.44 | $12.11 |
| Average True Range (ATR) | 1.28 | 1.08 |
| MACD | -0.06 | -0.06 |
| Stochastic Oscillator | 60.30 | 31.90 |
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products segment includes consumer product revenue consisting of sales of small electric household and specialty housewares appliances whereas the health segment includes lease revenue associated with leases of connected devices to specialty pharmacy networks and pharmaceutical companies, as well as licensing revenue which grant customers the right to use software for healthcare management.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.